Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry

Circ Heart Fail. 2023 Jan;16(1):e010176. doi: 10.1161/CIRCHEARTFAILURE.122.010176. Epub 2022 Oct 31.

Jacob B Pierce¹, Zhen Li², Melissa A Greiner², Steven J Lippmann², N Chantelle Hardy², Xian Shen³, Mark Stampehl³, Robert J Mentz^{1

4}, Larry A Allen⁵, Pamela N Peterson^{6

7}, Gregg C Fonarow⁸, Emily C O'Brien^{1

4}, Stephen J Greene^{1

4}

¹ Department of Medicine (J.B.P., R.J.M., E.C.O., S.J.G.), Duke University School of Medicine, Durham, NC.
² Department of Population Health Sciences (Z.L., M.A.G., S.J.L., N.C.H.), Duke University School of Medicine, Durham, NC.
³ Novartis Pharmaceuticals Corporation, East Hanover, NJ (X.S., M.S.).
⁴ Duke Clinical Research Institute, Durham, NC (R.J.M., E.C.O., S.J.G.).
⁵ Palliative and Advanced Illness Research, Center and Department of Medicine, Pennsylvania Perelman School of Medicine, Philadelphia (L.A.A.).
⁶ Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (P.N.P.).
⁷ Division of Cardiology, Denver Health Hospital, CO (P.N.P.).
⁸ Department of Medicine, University of California Los Angeles (G.C.F.).

No abstract available

Keywords: ejection fraction; heart failure; sacubitril/valsartan.

Publication types